Clinical research
Researchers with the U.S. National Institutes of Allergy and Infectious Diseases (NIAID) published a letter in The New England Journal of Medicine describing the three-month immunogenicity levels in Moderna’s mRNA-1273 vaccine.
With 36 Janssen-sponsored studies and another nearly 50, it has supported, the Janssen Pharmaceutical Companies of Johnson & Johnson has a presence in more than 80 of the hematology studies presented at the 62nd American Society of Hematology (ASH) Annual Meeting & Exposition, December 5-8.
While promising, the study showed no difference between this combination regimen and physician’s choice of topotecan or cyclophosphamide/doxorubicin/vincristine (CAV) in terms of overall survival (OS).
Topline results from Agios Pharmaceuticals’ Phase III ACTIVATE trial show that treatment with mitapivat was associated with a significantly greater hemoglobin response compared with placebo in patients with pyruvate kinase deficiency.
Shares of Axsome were up more than 7% in premarket trading after the company announced positive, long-term results from its Phase III Major Depressive Disorder study that sets the company up for potential regulatory approval.
Despite a number of anti-psychotic medications available, there are no approved drugs to address underlying cognitive development issues. Cerevance aims to change that.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for December 1, 2020.
As the U.S. went into its Thanksgiving holiday week, clinical trial news was quieter than usual, although there was a lot of important news on the COVID-19 vaccine front. Here’s a look.
Despite the constant need for social distancing, mask-wearing, and the isolation and economic uncertainty that resulted from the outbreak, there is still much to be thankful for when families gather around a virtual table to break bread and carve the turkey this year.
MediciNova announced today that it received positive Optical Coherence Tomography (OCT) results from its SPRINT-MS Phase IIb trial of MN-166 (ibudilast) in multiple sclerosis (MS) subjects.
PRESS RELEASES